BeOne Medicines Showcases Expanding Oncology Pipeline With More Than 60 Presentations at ASCO and EHA 2026 BeOne Medicines Ltd. has announced a major presence at two of the world’s leading…
Baszucki Group Backs Oxford University Trial Exploring Ketogenic Therapy for Early Psychosis Baszucki Group has announced a £1.17 million grant to support a pioneering clinical trial at the University of…
Datroway Gains Landmark U.S. Approval for First-Line Treatment of Metastatic Triple-Negative Breast Cancer In a major advancement for breast cancer treatment, Daiichi Sankyo and AstraZeneca have announced that the U.S.…
ClearNote Health to Present New Validation Data for Avantect Pancreatic Cancer Test at ASCO 2026 ClearNote Health has announced that it will present new multi-cohort validation data for its Avantect…
Enhertu® Receives CHMP Recommendation for EU Approval in HER2-Positive Metastatic Solid Tumors Enhertu has received a positive recommendation for approval in the European Union from the Committee for Medicinal Products…
Henry Schein Appoints Dan Daniel as Independent Chairman Following Stanley Bergman’s Retirement Henry Schein has announced a major leadership transition as its Board of Directors elected William K. “Dan” Daniel…
Merck Secures CHMP Support for KEYTRUDA® Plus Padcev® in Muscle-Invasive Bladder Cancer Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products…
Gilead Wins CHMP Backing for Trodelvy® in First-Line Metastatic TNBC Treatment Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
ImmunityBio Survey Highlights Diverse Treatment Priorities Among Patients With BCG-Unresponsive NMIBC ImmunityBio has unveiled new patient survey findings that shed light on how individuals living with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk…
Veracyte to Present Practice-Changing Oncology Data at ASCO 2026 Highlighting Advances in Breast and Prostate Cancer Genomic Testing Veracyte announced that major new clinical data involving its Prosigna Breast and…
Natera Showcases Expansive Oncology Research Program at ASCO 2026, Highlighting Advances in MRD Testing and Precision Cancer Care Natera announced an extensive oncology research program for the 2026 Annual Meeting…
Vyriad has introduced G-Link, a modular platform designed to enhance T-cell targeted lentiviral vector delivery for both in vivo and ex vivo therapeutic applications. Vyriad, Inc. has introduced a new…